Vaccine

Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder

VANCOUVER, British Columbia, and BASEL, Switzerland, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company…

11 months ago

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage…

11 months ago

Message from Renovaro Bioscience, Inc.’s CEO, The Hon. Mark Dybul, MD

Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024LOS ANGELES, Jan. 16, 2024…

11 months ago

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…

11 months ago

Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex’s Immunotherapeutic Candidates with DEKA’s Intradermal Therapeutic Applicator

The DEKA Intradermal Therapeutic Applicator The DEKA Intradermal Therapeutic Applicator Emergex has entered into an agreement with DEKA Research &…

11 months ago

Defence Begins Trading on the OTCQB and Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or…

11 months ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of…

12 months ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™…

12 months ago

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery,…

12 months ago

Defence’s AccuTOX(R) Impairs Lung Cancer Growth

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the…

12 months ago